{"id":"https://openalex.org/W4367668601","doi":"https://doi.org/10.1093/oncolo/oyad029","title":"A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies","display_name":"A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies","publication_year":2023,"publication_date":"2023-05-02","ids":{"openalex":"https://openalex.org/W4367668601","doi":"https://doi.org/10.1093/oncolo/oyad029","pmid":"https://pubmed.ncbi.nlm.nih.gov/37129455","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10322128"},"language":"en","primary_location":{"id":"doi:10.1093/oncolo/oyad029","doi":"https://doi.org/10.1093/oncolo/oyad029","is_oa":true,"landing_page_url":"https://doi.org/10.1093/oncolo/oyad029","pdf_url":"https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad029/50169335/oyad029.pdf","source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad029/50169335/oyad029.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049294543","display_name":"Melissa Lynne Johnson","orcid":"https://orcid.org/0000-0001-9874-1314","observed_orcids":["https://orcid.org/0000-0001-9874-1314"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Melissa L Johnson","raw_affiliation_strings":["Sarah Cannon Research Institute , Nashville, TN , USA","Tennessee Oncology , Nashville, TN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"Tennessee Oncology , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005718112","display_name":"Manish R. Patel","orcid":"https://orcid.org/0000-0001-6836-2364","observed_orcids":["https://orcid.org/0000-0001-6836-2364"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manish R Patel","raw_affiliation_strings":["Florida Cancer Specialists , Sarasota, FL , USA","Sarah Cannon Research Institute , Nashville, TN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists , Sarasota, FL , USA","institution_ids":[]},{"raw_affiliation_string":"Sarah Cannon Research Institute , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110806811","display_name":"Raid M. Aljumaily","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4390039380","display_name":"OU Health Stephenson Cancer Center","ror":"https://ror.org/02bmcqd02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039271","https://openalex.org/I4390039380"]},{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raid Aljumaily","raw_affiliation_strings":["Sarah Cannon Research Institute , Nashville, TN , USA","Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, OK , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, OK , USA","institution_ids":["https://openalex.org/I4390039380","https://openalex.org/I49332381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076615101","display_name":"Suzanne Fields Jones","orcid":"https://orcid.org/0000-0001-6881-8050","observed_orcids":["https://orcid.org/0000-0001-6881-8050"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suzanne F Jones","raw_affiliation_strings":["Sarah Cannon Research Institute , Nashville, TN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard A Burris, III","raw_affiliation_strings":["Sarah Cannon Research Institute , Nashville, TN , USA","Tennessee Oncology , Nashville, TN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"Tennessee Oncology , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018054038","display_name":"David Robert Spigel","orcid":"https://orcid.org/0000-0003-3215-9465","observed_orcids":["https://orcid.org/0000-0003-3215-9465"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David R Spigel","raw_affiliation_strings":["Sarah Cannon Research Institute , Nashville, TN , USA","Tennessee Oncology , Nashville, TN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"Tennessee Oncology , Nashville, TN , USA","institution_ids":["https://openalex.org/I4210135086"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5049294543"],"corresponding_institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"],"apc_list":{"value":3494,"currency":"USD","value_usd":3494},"apc_paid":{"value":3494,"currency":"USD","value_usd":3494},"fwci":1.0642,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.73302379,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"28","issue":"7","first_page":"640","last_page":"e559"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9282000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9282000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.025200000032782555,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.016499999910593033,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lcl161","display_name":"LCL161","score":0.9980000257492065},{"id":"https://openalex.org/keywords/topotecan","display_name":"topotecan","score":0.8759999871253967},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.8690000176429749},{"id":"https://openalex.org/keywords/relapsed-refractory-cancer","display_name":"relapsed/refractory cancer","score":0.8769999742507935},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.8980000019073486},{"id":"https://openalex.org/keywords/gynecologic-cancer","display_name":"gynecologic cancer","score":0.953000009059906},{"id":"https://openalex.org/keywords/oral-topotecan","display_name":"oral topotecan","score":0.7080000042915344},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7329999804496765},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.796999990940094},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9160000085830688},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9800000190734863},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.7879999876022339},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8040000200271606},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.9599999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9768049716949463},{"id":"https://openalex.org/C2781209748","wikidata":"https://www.wikidata.org/wiki/Q419953","display_name":"Topotecan","level":3,"score":0.9402444362640381},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6752298474311829},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.486637681722641},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4858343303203583},{"id":"https://openalex.org/C2777088508","wikidata":"https://www.wikidata.org/wiki/Q944777","display_name":"Endometrial cancer","level":3,"score":0.4451267123222351},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.43810051679611206},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4289499521255493},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4247058033943176},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4178805649280548},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.40613794326782227},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39546382427215576},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3924173414707184},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.32940205931663513},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005833","descriptor_name":"Genital Neoplasms, Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019772","descriptor_name":"Topotecan","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D055752","descriptor_name":"Small Cell Lung Carcinoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1093/oncolo/oyad029","doi":"https://doi.org/10.1093/oncolo/oyad029","is_oa":true,"landing_page_url":"https://doi.org/10.1093/oncolo/oyad029","pdf_url":"https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad029/50169335/oyad029.pdf","source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10322128","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10322128","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10322128/pdf/oyad029.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"},{"id":"pmid:37129455","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37129455","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The oncologist","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1093/oncolo/oyad029","doi":"https://doi.org/10.1093/oncolo/oyad029","is_oa":true,"landing_page_url":"https://doi.org/10.1093/oncolo/oyad029","pdf_url":"https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad029/50169335/oyad029.pdf","source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4367668601.pdf","grobid_xml":"https://content.openalex.org/works/W4367668601.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W1854574445","https://openalex.org/W1878670617","https://openalex.org/W1919288105","https://openalex.org/W2020857691","https://openalex.org/W2023056845","https://openalex.org/W2048573204","https://openalex.org/W2076024279","https://openalex.org/W2076307253","https://openalex.org/W2147744317","https://openalex.org/W2168664391","https://openalex.org/W2520986273","https://openalex.org/W2524835388","https://openalex.org/W2601834482"],"related_works":["https://openalex.org/W2980116994","https://openalex.org/W2370292009","https://openalex.org/W2060339005","https://openalex.org/W2043209027","https://openalex.org/W1979851514","https://openalex.org/W2741957550","https://openalex.org/W2158094535","https://openalex.org/W2099756452","https://openalex.org/W2144253411","https://openalex.org/W2096495293"],"abstract_inverted_index":{"BACKGROUND:":[0],"This":[1],"was":[2,48,62,111,130,139,172,188],"an":[3],"open-label,":[4],"multicenter,":[5],"single-arm":[6],"phase":[7,150],"Ib":[8],"dose-escalation":[9],"study":[10,138,187],"of":[11,35,57,70,77,102,109,133,159],"oral":[12,18,162],"LCL161":[13,41,47,160],"administered":[14,49,63],"in":[15,20,44,82],"combination":[16,181],"with":[17,22,40,174],"topotecan":[19,43,61,163],"patients":[21,37,79,86,90,95,134],"relapsed/refractory":[23],"small":[24],"cell":[25],"lung":[26],"cancer":[27],"(SCLC)":[28],"and":[29,42,55,93,126,148],"select":[30],"gynecological":[31],"cancers.":[32],"METHODS:":[33],"Cohorts":[34],"3-6":[36],"initiated":[38],"treatment":[39,110],"escalating":[45],"doses.":[46],"orally":[50,64],"on":[51],"days":[52,69],"1,":[53],"8,":[54],"15":[56],"each":[58,71],"21-day":[59,72],"cycle;":[60],"for":[65],"the":[66,143,179],"first":[67],"5":[68],"cycle.":[73],"RESULTS:":[74],"A":[75],"total":[76],"35":[78],"were":[80,87,104,123,154],"enrolled":[81],"6":[83],"cohorts;":[84],"30":[85],"female;":[88],"4":[89],"had":[91,96,135],"SCLC":[92],"19":[94],"ovarian":[97],"cancer.":[98],"Median":[99,107],"prior":[100],"lines":[101],"therapy":[103],"3":[105],"(1-10).":[106],"duration":[108],"7.1":[112],"weeks":[113],"(0.1-174).":[114],"The":[115,137,157,186],"most":[116],"frequent":[117],"grade":[118],"3/4":[119],"treatment-related":[120],"adverse":[121],"events":[122],"thrombocytopenia":[124],"(51.43%)":[125],"anemia":[127],"(31.43%).":[128],"ORR":[129],"9.7%;":[131],"58%":[132],"SD.":[136],"stopped":[140],"early":[141,190],"before":[142],"maximum":[144],"tolerated":[145],"dose":[146,152],"(MTD)":[147],"recommended":[149],"II":[151],"(RP2D)":[153],"determined.":[155],"CONCLUSION:":[156],"addition":[158],"to":[161],"caused":[164],"more":[165],"myelosuppression":[166],"when":[167],"dosed":[168],"together":[169],"than":[170],"what":[171],"associated":[173],"either":[175],"drug":[176,180],"alone.":[177],"Moreover,":[178],"did":[182],"not":[183],"improve":[184],"outcomes.":[185],"terminated":[189],"(ClinicalTrials.gov":[191],"Identifier:":[192],"NCT02649673).":[193]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-05-03T00:00:00"}